Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3112505 | 0.98 | HTR4 (0.55) | HTR4TP53ALOX15RAB9AL3MBTL1 | |
| SCHEMBL2061387 | 0.88 | ROCK2 (0.60) | HTR4TP53RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL13175534 | 0.88 | HTR4 (0.53) | HTR4TP53RAB9AL3MBTL1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1613928 | 0.87 | ROCK2 (0.58) | HTR4TP53RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3109286 | 0.86 | TP53 (0.53) | TP53ALOX15RAB9AL3MBTL1MAPT | |
| SCHEMBL918685 | 0.85 | NR1H4 (0.64) | TP53RAB9AL3MBTL1SMN1; SMN2NR1H4 | |
| SCHEMBL5678411 | 0.85 | CA1 (0.56) | HTR4ALOX15L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL12426338 | 0.85 | POLB (0.52) | HTR4TP53RAB9AMAPTMEN1 | |
| SCHEMBL5678384 | 0.85 | SMPD1 (0.60) | HTR4TP53RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3033838 | 0.85 | TP53 (0.67) | HTR4TP53RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-119161345-A | Tetrahydropteridinone derivatives as selective covalent inhibitors of Plk1 kinase | 润药仁智(北京)科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024086809-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-8461149-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2010542-B1 | 4,5-DIHYDRO-[1,2,4]TRIAZOLO[4,3-F]PTERIDINES AS PLK1 PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| WO-2011038185-A2 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | WO | disclosed |
| CN-101952291-A | 4-(9-(3, 3-difluorocyclopentyl)-5,7, 7-trimethyl-6-oxo-6, 7,8, 9-tetrahydro-5H-pyrimidino [4,5-B] [1,4] diaza-2-ylamino)-3-methoxybenzamide derivatives useful as inhibitors of human protein kinases PLK1 to PLK4 for the treatment of proliferative diseases | VERTEX PHARMA | 2011-01-19 | — | — | CN | disclosed |
| EP-2190849-A2 | COMPOUNDS USEFUL AS PROTEIN KINASES INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009023269-A2 | 4-(9-(3, 3-DIFLUOROCYCLOPENTYL) -5, 7, 7-TRIMETHYL-6-OXO-6, 7, 8, 9-TETRAHYDRO-5H-PYRIMIDO [4, 5-B[1, 4] DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023269-A2 | 4-(9-(3, 3-DIFLUOROCYCLOPENTYL) -5, 7, 7-TRIMETHYL-6-OXO-6, 7, 8, 9-TETRAHYDRO-5H-PYRIMIDO [4, 5-B[1, 4] DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2007120752-A2 | 4, 5-DIHYDRO- [1, 2, 4] TRIAZOLO [4, 3-F] PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR4 2753/4885TP53 2194/4885ALOX15 2913/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR4 2181/4885TP53 1378/4885ALOX15 2680/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR4 2753/4885TP53 2194/4885ALOX15 2913/4885 |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | MAP3K20, PRKCH, PACSIN2 | HTR4 4601/4885TP53 525/4885ALOX15 4044/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HTR4 2458/4885TP53 2073/4885ALOX15 2780/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HTR4 2458/4885TP53 2073/4885ALOX15 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.